{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:14:36Z","timestamp":1785521676746,"version":"3.56.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012112","name":"SOBI","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100019531","name":"Apellis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03614-3","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:59:27Z","timestamp":1778853567000},"page":"3385-3402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3704-0922","authenticated-orcid":false,"given":"Bradley P.","family":"Dixon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-1667","authenticated-orcid":false,"given":"Andrew S.","family":"Bomback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4717-5855","authenticated-orcid":false,"given":"Carly","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5835-8599","authenticated-orcid":false,"given":"Zalmai","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4574-2385","authenticated-orcid":false,"given":"Mingyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3366-9619","authenticated-orcid":false,"given":"Kathryn","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-1171","authenticated-orcid":false,"given":"Piotr","family":"Wojciechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9936-0932","authenticated-orcid":false,"given":"Wojciech","family":"Margas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7865-2051","authenticated-orcid":false,"given":"Rose","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-6687","authenticated-orcid":false,"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-9663","authenticated-orcid":false,"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5390-8002","authenticated-orcid":false,"given":"Fadi","family":"Fakhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"6","key":"3614_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000507254","volume":"144","author":"F Caravaca-Font\u00e1n","year":"2020","unstructured":"Caravaca-Font\u00e1n F, Lucientes L, Cavero T, Praga M. Update on C3 glomerulopathy: a complement-mediated disease. Nephron. 2020;144(6):272\u201380.","journal-title":"Nephron"},{"issue":"4","key":"3614_CR2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.ekir.2025.01.024","volume":"10","author":"F Caravaca-Font\u00e1n","year":"2025","unstructured":"Caravaca-Font\u00e1n F, Toledo-Rojas R, Huerta A, et al. Comparative analysis of proteinuria and longitudinal outcomes in immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Kidney Int Rep. 2025;10(4):1223\u201336.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"3614_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ekir.2023.12.007","volume":"9","author":"B Tarragon Estebanez","year":"2024","unstructured":"Tarragon Estebanez B, Bomback AS. C3 glomerulopathy: novel treatment paradigms. Kidney Int Rep. 2024;9(3):569\u201379.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"3614_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","volume":"93","author":"AS Bomback","year":"2018","unstructured":"Bomback AS, Santoriello D, Avasare RS, et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int. 2018;93(4):977\u201385.","journal-title":"Kidney Int"},{"key":"3614_CR5","unstructured":"Orphanet. C3 glomerulopathy. 2021. https:\/\/www.orpha.net\/en\/disease\/detail\/329918?name=c3g&mode=name. Accessed 1 July 2025."},{"issue":"3","key":"3614_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","volume":"15","author":"RJH Smith","year":"2019","unstructured":"Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15(3):129\u201343.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"3614_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/ckj\/sfz073","volume":"13","author":"N Garam","year":"2020","unstructured":"Garam N, Proh\u00e1szka Z, Szil\u00e1gyi \u00c1, et al. Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. Clin Kidney J. 2020;13(2):225\u201334.","journal-title":"Clin Kidney J"},{"issue":"4","key":"3614_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais A, No\u00ebl LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454\u201364.","journal-title":"Kidney Int"},{"issue":"12","key":"3614_CR9","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1007\/s00467-024-06476-5","volume":"39","author":"C Patry","year":"2024","unstructured":"Patry C, Webb NJA, Fei\u00dft M, et al. Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network. Pediatr Nephrol. 2024;39(12):3569\u201380.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"3614_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ekir.2024.09.017","volume":"10","author":"AS Bomback","year":"2025","unstructured":"Bomback AS, Charu V, Fakhouri F. Challenges in the diagnosis and management of immune complex-mediated membranoproliferative glomerulonephritis and complement 3 glomerulopathy. Kidney Int Rep. 2025;10(1):17\u201328.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3614_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000542354","volume":"4","author":"EK Magliulo","year":"2024","unstructured":"Magliulo EK, Ravipati P. C3 glomerulopathy: a current perspective in an evolving landscape. Glomerular Dis. 2024;4(1):200\u201310.","journal-title":"Glomerular Dis"},{"issue":"2","key":"3614_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/nep.70001","volume":"30","author":"GL Guzman","year":"2025","unstructured":"Guzman GL, Perry KW. Pegcetacoplan for the treatment of paediatric C3 glomerulonephritis: a case report. Nephrology. 2025;30(2):e70001.","journal-title":"Nephrology"},{"key":"3614_CR13","doi-asserted-by":"crossref","unstructured":"Bartoli G, Dello Strologo A, Grandaliano G, Pesce F. Updates on C3 glomerulopathy in kidney transplantation: pathogenesis and treatment options. Int J Mol Sci. 2024.","DOI":"10.3390\/ijms25126508"},{"issue":"12","key":"3614_CR14","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","volume":"81","author":"SM Hoy","year":"2021","unstructured":"Hoy SM. Pegcetacoplan: first approval. Drugs. 2021;81(12):1423\u201330.","journal-title":"Drugs"},{"issue":"1","key":"3614_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","volume":"10","author":"AS Bomback","year":"2025","unstructured":"Bomback AS, Daina E, Remuzzi G, et al. Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis. Kidney Int Rep. 2025;10(1):87\u201398.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"3614_CR16","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","volume":"8","author":"BP Dixon","year":"2023","unstructured":"Dixon BP, Greenbaum LA, Huang L, et al. Clinical safety and efficacy of pegcetacoplan in a Phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases. Kidney Int Rep. 2023;8(11):2284\u201393.","journal-title":"Kidney Int Rep"},{"key":"3614_CR17","unstructured":"Fakhouri F, Bomback A, Kavanagh D, et al. Pegcetacoplan maintains early improvements in post-transplant recurrent C3G and IC-MPGN: 1-year results from the Phase II NOBLE trial. 61st ERA Congress; 23\u201326 May 2024; Stockholm, Sweden."},{"issue":"22","key":"3614_CR18","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","volume":"393","author":"F Fakhouri","year":"2025","unstructured":"Fakhouri F, Bomback AS, Ariceta G, et al. Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN. N Engl J Med. 2025;393(22):2210\u201320.","journal-title":"N Engl J Med"},{"key":"3614_CR19","doi-asserted-by":"crossref","unstructured":"Nester CM, Bomback AS, Ariceta Iraola MG, et al. VALIANT: a randomized, multicenter, double-blind, placebo (PBO)-controlled, Phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). ASN Annual Meeting; 24\u201327 October 2024; San Diego, CA, USA.","DOI":"10.1681\/ASN.2024qdwvz5bg"},{"key":"3614_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1537974","volume":"16","author":"D Kavanagh","year":"2025","unstructured":"Kavanagh D, Barratt J, Schubart A, Webb NJA, Meier M, Fakhouri F. Factor B as a therapeutic target for the treatment of complement-mediated diseases. Front Immunol. 2025;16:1537974.","journal-title":"Front Immunol"},{"issue":"10","key":"3614_CR21","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","volume":"7","author":"AS Bomback","year":"2022","unstructured":"Bomback AS, Kavanagh D, Vivarelli M, et al. Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial. Kidney Int Rep. 2022;7(10):2150\u20139.","journal-title":"Kidney Int Rep"},{"issue":"16","key":"3614_CR22","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1073\/pnas.1820892116","volume":"116","author":"A Schubart","year":"2019","unstructured":"Schubart A, Anderson K, Mainolfi N, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116(16):7926\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3614_CR23","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","volume":"8","author":"E Wong","year":"2023","unstructured":"Wong E, Nester C, Cavero T, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy. Kidney Int Rep. 2023;8(12):2754\u201364.","journal-title":"Kidney Int Rep"},{"issue":"10512","key":"3614_CR24","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","volume":"406","author":"D Kavanagh","year":"2025","unstructured":"Kavanagh D, Bomback AS, Vivarelli M, et al. Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, Phase 3 study. Lancet. 2025;406(10512):1587\u201398.","journal-title":"Lancet"},{"key":"3614_CR25","unstructured":"Kavanagh D, Bomback AS, Vivarelli M, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy: results from the Phase 3 APPEAR-C3G study. 61st ERA Congress; 23\u201326 May 2024; Stockholm, Sweden."},{"key":"3614_CR26","unstructured":"Apellis Pharmaceuticals, Inc. Empaveli (pegcetacoplan) prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215014s000lbl.pdf. Accessed 2 July 2025."},{"key":"3614_CR27","unstructured":"Swedish Orphan Biovitrum AB. Aspaveli (pegcetacoplan) summary of product characteristics. 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aspaveli-epar-product-information_en.pdf. Accessed 26 Jan 2026."},{"key":"3614_CR28","unstructured":"Novartis Europharm Limited. Fabhalta (iptacopan) summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fabhalta-epar-product-information_en.pdf. Accessed 26 Jan 2026."},{"key":"3614_CR29","unstructured":"Novartis Pharmaceuticals Corporation. Fabhalta (iptacopan) prescribing information. 2025. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/fabhalta.pdf. Accessed 2 July 2025."},{"issue":"2","key":"3614_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/ndt\/gfad182","volume":"39","author":"M Noris","year":"2024","unstructured":"Noris M, Remuzzi G. C3G and Ig-MPGN-treatment standard. Nephrol Dial Transplant. 2024;39(2):202\u201314.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"3614_CR31","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753\u201379.","journal-title":"Kidney Int"},{"key":"3614_CR32","unstructured":"Clinicaltrials.gov. Study of efficacy and safety of iptacopan in patients with C3 glomerulopathy. (APPEAR-C3G). 2021. https:\/\/clinicaltrials.gov\/study\/NCT04817618?term=NCT04817618&rank=1. Accessed 23 June 2025."},{"issue":"6","key":"3614_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"3614_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s41669-023-00455-6","volume":"8","author":"B Macabeo","year":"2024","unstructured":"Macabeo B, Rotrou T, Millier A, Fran\u00e7ois C, Laram\u00e9e P. The acceptance of indirect treatment comparison methods in oncology by health technology assessment agencies in England, France, Germany, Italy, and Spain. Pharmacoecon Open. 2024;8(1):5\u201318.","journal-title":"Pharmacoecon Open"},{"issue":"10","key":"3614_CR35","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/14656566.2023.2215925","volume":"24","author":"M Merkel","year":"2023","unstructured":"Merkel M, Danese D, Chen C, et al. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother. 2023;24(10):1205\u201314.","journal-title":"Expert Opin Pharmacother"},{"key":"3614_CR36","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams K, Welton N. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. (Technical Support Documents). NICE Decision Support Unit. 2016. https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf. Accessed 6 July 2025."},{"issue":"6","key":"3614_CR37","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"key":"3614_CR38","doi-asserted-by":"crossref","unstructured":"Nester C, Smith R, Kavanagh D, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-month results from the Phase 3 APPEAR-C3G Study. ISN World Congress of Nephrology; 6\u20139 February 2025; Dwarka, New Delhi, India.","DOI":"10.1016\/j.ekir.2024.11.300"},{"issue":"9","key":"3614_CR39","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2215\/CJN.0000000000000505","volume":"19","author":"C Nester","year":"2024","unstructured":"Nester C, Decker DA, Meier M, et al. Developing therapies for C3 glomerulopathy: report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group. Clin J Am Soc Nephrol. 2024;19(9):1201\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"3614_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ekir.2025.10.020","volume":"11","author":"D Kavanagh","year":"2026","unstructured":"Kavanagh D, Ariceta G, Vivarelli M, et al. Current and emerging therapies for C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis. Kidney Int Rep. 2026;11(1):17\u201331.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"3614_CR41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.34067\/KID.0000000000000115","volume":"4","author":"F Caravaca-Font\u00e1n","year":"2023","unstructured":"Caravaca-Font\u00e1n F, Cavero T, D\u00edaz-Encarnaci\u00f3n M, et al. Clinical profiles and patterns of kidney disease progression in C3 glomerulopathy. Kidney360. 2023;4(5):659\u201372.","journal-title":"Kidney360."},{"issue":"7","key":"3614_CR42","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/ndt\/gfab075","volume":"37","author":"F Caravaca-Font\u00e1n","year":"2022","unstructured":"Caravaca-Font\u00e1n F, D\u00edaz-Encarnaci\u00f3n M, Cabello V, et al. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy. Nephrol Dial Transplant. 2022;37(7):1270\u201380.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3614_CR43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.kint.2025.06.003","volume":"108","author":"S Masoud","year":"2025","unstructured":"Masoud S, Wong K, Pitcher D, et al. Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry. Kidney Int. 2025;108(3):455\u201369.","journal-title":"Kidney Int"},{"issue":"2","key":"3614_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.10.028","volume":"11","author":"F Caravaca-Fontan","year":"2026","unstructured":"Caravaca-Fontan F, Fakhouri F, Licht C, Pickering MC, Schaefer F, Wong E. Delphi consensus on surrogate end points in C3 glomerulopathy and primary immune complex-mediated membranoproliferative glomerulonephritis. Kidney Int Rep. 2026;11(2):103671.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"3614_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/jmahp12020006","volume":"12","author":"B Macabeo","year":"2024","unstructured":"Macabeo B, Quen\u00e9chdu A, Aball\u00e9a S, Fran\u00e7ois C, Boyer L, Laram\u00e9e P. Methods for indirect treatment comparison: results from a systematic literature review. J Mark Access Health Policy. 2024;12(2):58\u201380.","journal-title":"J Mark Access Health Policy"},{"issue":"5","key":"3614_CR46","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1177\/0272989X20929309","volume":"40","author":"D Weber","year":"2020","unstructured":"Weber D, Jensen K, Kieser M. Comparison of methods for estimating therapy effects by indirect comparisons: a simulation study. Med Decis Making. 2020;40(5):644\u201354.","journal-title":"Med Decis Making"},{"key":"3614_CR47","unstructured":"Fakhouri F, Ariceta G, Bomback AS, et al. Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the Phase 3 VALIANT trial show sustained efficacy. 62nd ERA Congress; 4\u20137 June 2025; Vienna, Austria."},{"key":"3614_CR48","unstructured":"Smith R, Kavanagh D, Vivarelli M, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-month results from the Phase 3 APPEAR-C3G study. American Society of Nephrology (ASN) Kidney Week; 23\u201327 October 2024; San Diego, CA, USA."},{"key":"3614_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1566771","volume":"16","author":"Y He","year":"2025","unstructured":"He Y, Guo K, Xin J. Complement updates in optic neuritis. Front Neurol. 2025;16:1566771.","journal-title":"Front Neurol"},{"issue":"7","key":"3614_CR50","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/17512433.2022.2109462","volume":"15","author":"JW Lee","year":"2022","unstructured":"Lee JW, Brodsky RA, Nishimura JI, Kulasekararaj AG. The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments. Expert Rev Clin Pharmacol. 2022;15(7):851\u201361.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3614_CR51","doi-asserted-by":"crossref","unstructured":"Kavanagh D, Bomback AS, Ariceta G, et al. Pegcetacoplan demonstrates clinically significant responses in C3G and primary (idiopathic) IC-MPGN patients with or without concomitant immunosuppression in VALIANT. 62nd ERA Congress; 4\u20137 June 2025; Vienna, Austria.","DOI":"10.1093\/ndt\/gfaf116.020"},{"issue":"2","key":"3614_CR52","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"issue":"3","key":"3614_CR53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1017\/S0266462319000333","volume":"35","author":"DM Phillippo","year":"2019","unstructured":"Phillippo DM, Dias S, Elsada A, Ades AE, Welton NJ. Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence technology appraisals. Int J Technol Assess Health Care. 2019;35(3):221\u20138.","journal-title":"Int J Technol Assess Health Care"},{"issue":"11","key":"3614_CR54","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jval.2023.07.001","volume":"26","author":"O Cassidy","year":"2023","unstructured":"Cassidy O, Harte M, Trela-Larsen L, et al. A comparison of relative-efficacy estimate(s) derived from both matching-adjusted indirect comparisons and standard anchored indirect treatment comparisons: a review of matching-adjusted indirect comparisons. Value Health. 2023;26(11):1665\u201374.","journal-title":"Value Health"},{"issue":"3","key":"3614_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-091961","volume":"15","author":"JD Guo","year":"2025","unstructured":"Guo JD, Gehchan A, Hartzema A. Selection of indirect treatment comparisons for health technology assessments: a practical guide for health economics and outcomes research scientists and clinicians. BMJ Open. 2025;15(3):e091961.","journal-title":"BMJ Open"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03614-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03614-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03614-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:04:59Z","timestamp":1785517499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03614-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3614"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03614-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bradley Dixon reports consultancy from Apellis, Novartis, Alexion, AstraZeneca, Arrowhead, Calliditas, and Roche Genentech; Andrew Bomback reports consultancy and\/or honoraria from Achillion, Alexion, Amgen, Apellis, Aurinia, Calliditas, Catalyst, Genentech, GSK, Kezar, Novartis, Otsuka, Q32, Silence Therapeutics, UpToDate; Carly Rich and Zalmai Hakimi are employees of Sobi; Mingyi Huang and Kathryn Gordon are employees of Apellis; Piotr Wojciechowski and Wojciech Margas are employees of Clever Access; Rose Chang and Mei Sheng Duh are employees of the Analysis Group, Inc.; Fernando Caravaca-Font\u00e1n reports consultancy and\/or honoraria from Alexion, Apellis, AstraZeneca, Novartis, Otsuka, STADA, Sobi, Bayer; Fadi Fakhouri reports consultancy and\/or honoraria from Alexion, Apellis, AstraZeneca, Novartis, Roche, Sanofi, Sobi.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a post hoc analysis and modeling of data already collected and\/or published de-identified data. Original studies were approved by the relevant institutional review boards at each study site and were carried out in accordance with the International Conference on Harmonisation good clinical practice guidelines and the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}